Sometimes companies find that they have overlapping needs, and such was the case recently in the drug world. Abbott Labs (NYSE: ABT ) was looking to reinvigorate its branded generic drug business, while Mylan (NASDAQ: MYL )
wanted to join the parade of companies that have redomiciled in Europe
to avoid taxes. The two companies came together on Monday in a $5
billion deal that will see Abbott sell its developed market drug
business in a stock transaction that also gives Mylan the European tax
base it wanted.
Continue reading here:
Abbott And Mylan: Winners and Winners?
No comments:
Post a Comment